Camlin Fine Sciences Limited has informed the Exchange regarding 'Press Release issued by the Company'.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 2.1 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Camlin Fine Sciences' board has approved issuing up to 41,06,181 fully paid equity shares at ₹247.69 per share, aggregating to about ₹101.71 crore. These shares will be issued as non-cash consideration to the sellers of Vinpai, a French listed company, towards acquiring a majority stake (block acquisition) at €3.60 per Vinpai share. The new shares will represent approximately 2.14% of CFSL's post-issue share capital. Shareholders' approval will be sought via postal ballot with voting concluding on October 29, 2025, and allotment is expected on or before November 12, 2025. Following the block acquisition, CFSL plans to launch a cash tender offer (OPAS) for the remaining Vinpai shares at the same price.
Existing shareholders will see a modest dilution of around 2.14% but no cash outflow is involved since the shares are issued as acquisition consideration. The deal expands CFSL's footprint into the European specialty ingredients market through Vinpai, though completion still depends on shareholder approval and regulatory clearances.